Intestinal Disorders News

A phase 3 randomized controlled trial showed no benefit of the probiotic Bifidobacterium breve BBG-001 for preventing necrotizing enterocolitis, late-onset sepsis and mortality in very preterm infants.

HONOLULU — Chronic constipation was found to be associated with gastrointestinal complications among younger patients in a retrospective study presented at ACG 2015.

The persistence of elevated white blood cells, or blood eosinophilia, in preterm infants with necrotizing enterocolitis served as an indicator of potential severe adverse events, according to research in Neonatology.

Daily supplementation with vitamin D, calcium or both did not significantly decrease risk for recurrent colorectal adenomas, according to the results of a randomized, double blind, placebo-controlled trial.

Naia Rare Diseases Inc. successfully completed a pre-Investigational New Drug meeting with the FDA, which agreed to the company’s clinical development plans for NB1001, its long-acting glucagon-like peptide-1 receptor agonist for treating patients with short bowel syndrome, according to a press release.

Mayo Clinic researchers have performed a systematic review and meta-analysis which identified three new tests that can serve as biomarkers for idiopathic bile acid diarrhea in patients with diarrhea-predominant functional bowel disorders.

Patients with obesity who underwent right hemicolectomy with single-port laparoscopy had comparable short-term outcomes and complications to nonobese patients in a recent study.

The FDA has recently issued a number of gastroenterology-relevant communications, including bariatric and esophageal ablation device approvals, orphan drug designations for several cholangiocarcinoma treatments, fast track designation for a familial adenomatous polyposis drug, a draft guidance on clinical evaluation of gastroparesis drugs, and additional safety measures for ERCP duodenoscope reprocessing.

Trimethylamine-N-oxide, an organic compound produced by intestinal bacteria, was associated with coronary atherosclerosis burden and mortality among patients with chronic kidney disease in a recent study.

The FDA has granted fast track designation to CEQ508, an investigational RNAi therapeutic for familial adenomatous polyposis, the manufacturer announced.